AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|
26.7 C
New York
Friday, September 11, 2026

Tag: rights

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Allspring Closed-End Funds Declare Monthly Distributions and Announce a Portfolio Manager Change

CHARLOTTE, N.C., July 25, 2025 /PRNewswire/ -- The Allspring Income Opportunities Fund (NYSE American: EAD), the Allspring Multi-Sector Income Fund (NYSE American: ERC), and...

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to...

ATLANTA, July 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Vonage Receives Recognition from Gartner® for Communications Platform as a Service: Named a Customers’ Choice and a Visionary

Customers worldwide recommend Vonage's Communications Platform as a Service (CPaaS), receiving a Gartner Customers' Choice recognition; company recognized as a Visionary in the Gartner...

First Hawaiian, Inc. Reports Second Quarter 2025 Financial Results and Declares Dividend

HONOLULU, July 25, 2025 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ:FHB), (“First Hawaiian” or the “Company”) today reported financial results for its quarter ended June 30, 2025.

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.

RDDT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Reddit, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in...

New York, July 24, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Reddit, Inc. (NYSE: RDDT) between October 29, 2024 and May 20, 2025, both dates inclusive (the “Class Period”), of the important August 18, 2025 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Petco Health and Wellness Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action –...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline.

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRights